6-Azuridine (Synonyms: 6-Azauridine)

目录号: HY-131611 纯度: 99.83%: FAQs
Data Sheet SDS COA 产品使用指南技术支持

6-Azuridine (6-Azauridine) 是一种口服活性的嘌呤核苷类似物。6-Azuridine 可激活 autophagic flux，诱导依赖于AMPK 和 p53 的凋亡 (Apoptosis)。6-Azuridine 具有抗肿瘤和抗病毒活性。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

6-Azuridine Chemical Structure

CAS No. : 54-25-1

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥680	In-stock
500 mg	￥620	In-stock
1 g	￥980	In-stock
5 g		询价
10 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

6-Azuridine 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 AMPK 亚型特异性产品:

查看所有亚型

NUAK1 NUAK2 AMPK AMPK α1β1γ1 AMPK α2β1γ1 AMPK α1β2γ1 AMPK α2β2γ1

生物活性
纯度 & 产品资料
参考文献

生物活性

6-Azuridine (6-Azauridine) is an orally active purine nucleoside analogue. 6-Azuridine activates autophagic flux, induces Apoptosis that depends on AMPK and p53. 6-Azuridine exhibit both antitumor and antiviral activities^[1]^[2]^[3]^[4]^[5]^[6].

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
BHK-21	EC₅₀	> 100 μM Compound: NM299	Antiviral activity against Reo-1 virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against Reo-1 virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 26443549]
BHK-21	EC₅₀	> 100 μM Compound: NM 299	Antiviral activity against Yellow fever virus infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against Yellow fever virus infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 25082514]
BHK-21	EC₅₀	> 100 μM Compound: NM 299	Antiviral activity against Reovirus type-1 infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against Reovirus type-1 infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 25082514]
BHK-21	EC₅₀	> 100 μM Compound: NM 299	Antiviral activity against Reovirus-1 infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay Antiviral activity against Reovirus-1 infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay	[PMID: 19482481]
BHK-21	CC₅₀	> 100 μM Compound: NM 299	Cytotoxicity against mock-infected BHK21 cells after 48 to 96 hrs by MTT assay Cytotoxicity against mock-infected BHK21 cells after 48 to 96 hrs by MTT assay	[PMID: 25082514]
BHK-21	CC₅₀	> 100 μM Compound: NM 299	Cytotoxicity against hamster BHK21 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay Cytotoxicity against hamster BHK21 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay	[PMID: 19482481]
BHK-21	CC₅₀	> 100 μM Compound: 6-Azauridine	Cytotoxicity against golden hamster BHK21 cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against golden hamster BHK21 cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 29028528]
BHK-21	CC₅₀	> 100 μM Compound: NM 299	Cytotoxicity against hamster BHK21 cells assessed as cell viability after 72 hrs by MTT method Cytotoxicity against hamster BHK21 cells assessed as cell viability after 72 hrs by MTT method	[PMID: 25913116]
BHK-21	EC₅₀	26 μM Compound: NM299	Antiviral activity against YFV infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against YFV infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 26443549]
BHK-21	EC₅₀	26 μM Compound: NM 299	Antiviral activity against Yellow fever virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay Antiviral activity against Yellow fever virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay	[PMID: 19482481]
BHK-21	EC₅₀	26 μM Compound: 6-azauridine	Antiviral activity against YFV infected in BHK21 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against YFV infected in BHK21 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 18760610]
BHK-21	EC₅₀	46 μM Compound: NM 299	Antiviral activity against YFV infected in hamster BHK21 cells assessed as protection against viral-induced cytopathogenecity after 3 to 4 days by MTT method Antiviral activity against YFV infected in hamster BHK21 cells assessed as protection against viral-induced cytopathogenecity after 3 to 4 days by MTT method	[PMID: 25913116]
MT4	CC₅₀	0.2 μM Compound: NM 299	Cytotoxicity against human MT4 cells after 96 hrs by MTT method Cytotoxicity against human MT4 cells after 96 hrs by MTT method	[PMID: 18054491]
MT4	CC₅₀	2 μM Compound: NM299	Cytotoxicity against human MT4 cells assessed as cell viability after 96 hrs by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability after 96 hrs by MTT assay	[PMID: 26443549]
MT4	CC₅₀	2 μM Compound: NM 299	Cytotoxicity against mock-infected human MT4 cells after 96 hrs by MTT assay Cytotoxicity against mock-infected human MT4 cells after 96 hrs by MTT assay	[PMID: 25082514]
MT4	CC₅₀	2 μM Compound: 6-Azauridine	Cytotoxicity against human MT4 cells after 96 hrs by MTT assay Cytotoxicity against human MT4 cells after 96 hrs by MTT assay	[PMID: 20359898]
MT4	CC₅₀	2 μM Compound: NM 299	Cytotoxicity against human MT4 cells after 96 hrs by MTT assay Cytotoxicity against human MT4 cells after 96 hrs by MTT assay	[PMID: 20359898]
MT4	CC₅₀	2 μM Compound: NM 299	Cytotoxicity against human MT4 cells after 96 hrs by MTT assay Cytotoxicity against human MT4 cells after 96 hrs by MTT assay	[PMID: 19482481]
MT4	CC₅₀	2 μM Compound: 6-azauridine	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 96 hrs by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 96 hrs by MTT assay	[PMID: 18760610]
Vero	CC₅₀	> 10 μM Compound: 6-Azauridine	Cytotoxicity against African green monkey Vero cells measured after 3 days by CelltiterGlo luminescence assay Cytotoxicity against African green monkey Vero cells measured after 3 days by CelltiterGlo luminescence assay	[PMID: 29277307]
Vero	EC₅₀	> 100 μM Compound: NM 299	Antiviral activity against Poliovirus type 1 Sabin strain infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay Antiviral activity against Poliovirus type 1 Sabin strain infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	> 100 μM Compound: NM 299	Antiviral activity against Vesicular stomatitis virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay Antiviral activity against Vesicular stomatitis virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	> 100 μM Compound: NM 299	Antiviral activity against Coxsackievirus B5 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay Antiviral activity against Coxsackievirus B5 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	> 100 μM Compound: NM 299	Antiviral activity against HSV1 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay Antiviral activity against HSV1 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	> 20 μM Compound: NM 299	Antiviral activity against Polio virus type1 Sabin strain Chat infected in african green monkey Vero cells after 2 days by plaque reduction assay Antiviral activity against Polio virus type1 Sabin strain Chat infected in african green monkey Vero cells after 2 days by plaque reduction assay	[PMID: 20359898]
Vero	EC₅₀	> 20 μM Compound: 6-Azauridine	Antiviral activity against Polio virus type1 Sabin strain Chat infected in african green monkey Vero cells after 2 days by plaque reduction assay Antiviral activity against Polio virus type1 Sabin strain Chat infected in african green monkey Vero cells after 2 days by plaque reduction assay	[PMID: 20359898]
Vero	EC₅₀	> 20 μM Compound: 6-Azauridine	Antiviral activity against Human coxsackievirus B2 Ohio-1 infected in african green monkey Vero cells after 3 days by plaque reduction assay Antiviral activity against Human coxsackievirus B2 Ohio-1 infected in african green monkey Vero cells after 3 days by plaque reduction assay	[PMID: 20359898]
Vero	EC₅₀	> 20 μM Compound: NM 299	Antiviral activity against Human coxsackievirus B2 Ohio-1 infected in african green monkey Vero cells after 3 days by plaque reduction assay Antiviral activity against Human coxsackievirus B2 Ohio-1 infected in african green monkey Vero cells after 3 days by plaque reduction assay	[PMID: 20359898]
Vero	EC₅₀	> 20 μM Compound: 6-Azauridine	Antiviral activity against HSV1 KOS infected in african green monkey Vero cells after 3 days by plaque reduction assay Antiviral activity against HSV1 KOS infected in african green monkey Vero cells after 3 days by plaque reduction assay	[PMID: 20359898]
Vero	EC₅₀	> 20 μM Compound: NM 299	Antiviral activity against HSV1 KOS infected in african green monkey Vero cells after 3 days by plaque reduction assay Antiviral activity against HSV1 KOS infected in african green monkey Vero cells after 3 days by plaque reduction assay	[PMID: 20359898]
Vero	CC₅₀	≥ 12.5 μM Compound: 6-AUdr	Cytotoxicity against african green monkey Vero 76 cells after 48 to 96 hrs by crystal violet staining Cytotoxicity against african green monkey Vero 76 cells after 48 to 96 hrs by crystal violet staining	[PMID: 22047799]
Vero	CC₅₀	≥ 12.5 μM Compound: 6-aza-uridine	Cytotoxicity against african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay Cytotoxicity against african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay	[PMID: 22513121]
Vero	EC₅₀	0.9 μM Compound: NM 299	Antiviral activity against RSV infected in African green monkey Vero 76 cells after 5 days by plaque reduction assay Antiviral activity against RSV infected in African green monkey Vero 76 cells after 5 days by plaque reduction assay	[PMID: 25913116]
Vero	EC₅₀	1.2 μM Compound: 6-AUdr	Antiviral activity against Human respiratory syncytial virus A2 infected in african green monkey Vero 76 cells assessed as reduction of virus-induced plaque formation after 5 days using crystal violet staining Antiviral activity against Human respiratory syncytial virus A2 infected in african green monkey Vero 76 cells assessed as reduction of virus-induced plaque formation after 5 days using crystal violet staining	[PMID: 22047799]
Vero	EC₅₀	1.2 μM Compound: NM 299	Antiviral activity against Respiratory syncytial virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 5 days by plaque reduction assay Antiviral activity against Respiratory syncytial virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 5 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	1.2 μM Compound: NM 299	Antiviral activity against RSV A2 infected in african green monkey Vero cells after 5 days by plaque reduction assay Antiviral activity against RSV A2 infected in african green monkey Vero cells after 5 days by plaque reduction assay	[PMID: 20359898]
Vero	EC₅₀	1.2 μM Compound: 6-Azauridine	Antiviral activity against RSV A2 infected in african green monkey Vero cells after 5 days by plaque reduction assay Antiviral activity against RSV A2 infected in african green monkey Vero cells after 5 days by plaque reduction assay	[PMID: 20359898]
Vero	EC₅₀	1.4 μM Compound: 6-Azauridine	Antiviral activity against Rice stripe virus infected in African green monkey Vero 76 cells assessed as reduction of virus-plaque formation by crystal violet staining Antiviral activity against Rice stripe virus infected in African green monkey Vero 76 cells assessed as reduction of virus-plaque formation by crystal violet staining	[PMID: 26119992]
Vero	EC₅₀	11 μM Compound: NM 299	Antiviral activity against Vaccinia Virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay Antiviral activity against Vaccinia Virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	11 μM Compound: NM 299	Antiviral activity against Vaccinia virus Elstree-Lister infected in african green monkey Vero cells after 3 days by plaque reduction assay Antiviral activity against Vaccinia virus Elstree-Lister infected in african green monkey Vero cells after 3 days by plaque reduction assay	[PMID: 20359898]
Vero	CC₅₀	20 μM Compound: NM 299	Cytotoxicity against african green monkey Vero 76 cells by crystal violet staining Cytotoxicity against african green monkey Vero 76 cells by crystal violet staining	[PMID: 19482481]
Vero	CC₅₀	20 μM Compound: 6-azauridine	Cytotoxicity against mock-infected african green monkey Vero76 cells assessed as reduction in cell viability after 96 hrs by MTT assay Cytotoxicity against mock-infected african green monkey Vero76 cells assessed as reduction in cell viability after 96 hrs by MTT assay	[PMID: 18760610]
Vero	EC₅₀	4.48 μM Compound: 6-azauridine	Antiviral activity against PEDV infected in African green monkey Vero cells assessed as reduction in virus-induced cytopathic effect after 72 hrs by MTT assay Antiviral activity against PEDV infected in African green monkey Vero cells assessed as reduction in virus-induced cytopathic effect after 72 hrs by MTT assay	[PMID: 26698879]
Vero	CC₅₀	57.26 μM Compound: 6-azauridine	Cytotoxicity against African green monkey Vero cells after 48 hrs by MTT assay Cytotoxicity against African green monkey Vero cells after 48 hrs by MTT assay	[PMID: 26698879]
Vero 76	EC₅₀	> 100 μM Compound: NM299	Antiviral activity against human CVB5 infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 3 days by plaque reduction assay Antiviral activity against human CVB5 infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 3 days by plaque reduction assay	[PMID: 26443549]
Vero 76	EC₅₀	> 100 μM Compound: NM299	Antiviral activity against Human poliovirus 1 Sabin infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity by plaque reduction assay Antiviral activity against Human poliovirus 1 Sabin infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity by plaque reduction assay	[PMID: 26443549]
Vero 76	CC₅₀	> 12.5 μM Compound: 6-AU	Cytotoxicity against mock-infected african green monkey Vero 76 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay Cytotoxicity against mock-infected african green monkey Vero 76 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay	[PMID: 27161176]
Vero 76	EC₅₀	> 20 μM Compound: 6-azauridine	Antiviral activity against CVB2 infected in Vero76 cells assessed as reduction in virus plaque formation after 4 days by MTT assay Antiviral activity against CVB2 infected in Vero76 cells assessed as reduction in virus plaque formation after 4 days by MTT assay	[PMID: 18760610]
Vero 76	EC₅₀	> 20 μM Compound: 6-azauridine	Antiviral activity against Sb1 virus infected in Vero76 cells assessed as reduction in virus plaque formation after 4 days by MTT assay Antiviral activity against Sb1 virus infected in Vero76 cells assessed as reduction in virus plaque formation after 4 days by MTT assay	[PMID: 18760610]
Vero 76	EC₅₀	> 20 μM Compound: NM 299	Antiviral activity against Coxsackie virus type B2 virus infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay Antiviral activity against Coxsackie virus type B2 virus infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay	[PMID: 19482481]
Vero 76	EC₅₀	> 20 μM Compound: NM 299	Antiviral activity against HSV1 infected in Vero-76 cells after 3 days by plaque reduction assay Antiviral activity against HSV1 infected in Vero-76 cells after 3 days by plaque reduction assay	[PMID: 19482481]
Vero 76	CC₅₀	≥ 12.5 μM Compound: Aza	Cytotoxicity against mock-infected African green monkey Vero 76 cells assessed as reduction in proliferation after 48 to 96 hrs by MTT method Cytotoxicity against mock-infected African green monkey Vero 76 cells assessed as reduction in proliferation after 48 to 96 hrs by MTT method	[PMID: 25014745]
Vero 76	EC₅₀	≥ 12.5 μM Compound: Aza	Antiviral activity against CVB-5 virus Faulkner ATCC VR-185 infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay Antiviral activity against CVB-5 virus Faulkner ATCC VR-185 infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay	[PMID: 26479028]
Vero 76	EC₅₀	1.2 μM Compound: 6-aza-uridine	Antiviral activity against Human respiratory syncytial virus A2 ATCC VR-1540 infected in african green monkey Vero-76 cells assessed as reduction in viral plaque after 5 days by crystal violet staining Antiviral activity against Human respiratory syncytial virus A2 ATCC VR-1540 infected in african green monkey Vero-76 cells assessed as reduction in viral plaque after 5 days by crystal violet staining	[PMID: 22513121]
Vero 76	EC₅₀	1.2 μM Compound: 6-azauridine	Antiviral activity against RSV infected in Vero76 cells assessed as reduction in virus plaque formation after 4 days by MTT assay Antiviral activity against RSV infected in Vero76 cells assessed as reduction in virus plaque formation after 4 days by MTT assay	[PMID: 18760610]
Vero 76	EC₅₀	1.2 μM Compound: Aza	Antiviral activity against VSV Indiana ATCC VR-158 infected in african green monkey Vero-76 cells after 2 days by plaque reduction assay Antiviral activity against VSV Indiana ATCC VR-158 infected in african green monkey Vero-76 cells after 2 days by plaque reduction assay	[PMID: 26479028]
Vero 76	EC₅₀	1.2 μM Compound: 6-AU	Antiviral activity against Respiratory syncytial virus A2 infected in Vero 76 cells after 5 days by crystal violet staining based plaque reduction assay Antiviral activity against Respiratory syncytial virus A2 infected in Vero 76 cells after 5 days by crystal violet staining based plaque reduction assay	[PMID: 27161176]
Vero 76	EC₅₀	1.2 μM Compound: NM299	Antiviral activity against human RSV infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by plaque reduction assay Antiviral activity against human RSV infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by plaque reduction assay	[PMID: 26443549]
Vero 76	EC₅₀	1.2 μM Compound: Aza	Antiviral activity against Human respiratory syncytial virus A2 ATCC VR-1540 infected in Vero 76 cells after 5 days by plaque reduction assays Antiviral activity against Human respiratory syncytial virus A2 ATCC VR-1540 infected in Vero 76 cells after 5 days by plaque reduction assays	[PMID: 25014745]
Vero 76	EC₅₀	1.2 μM Compound: NM 299	Antiviral activity against Respiratory syncytial virus A2 infected in Vero-76 cells after 5 days by plaque reduction assay Antiviral activity against Respiratory syncytial virus A2 infected in Vero-76 cells after 5 days by plaque reduction assay	[PMID: 19482481]
Vero 76	CC₅₀	10 μM Compound: NM 299	Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by MTT method Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by MTT method	[PMID: 25913116]
Vero 76	CC₅₀	12 μM Compound: 6-Azauridine	Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining	[PMID: 26119992]
Vero 76	CC₅₀	16 μM Compound: 6-Azauridine	Cytotoxicity against African green monkey Vero 76 cells assessed as decrease in cell viability after 48 to 96 hrs by MTT assay Cytotoxicity against African green monkey Vero 76 cells assessed as decrease in cell viability after 48 to 96 hrs by MTT assay	[PMID: 29028528]
Vero 76	CC₅₀	20 μM Compound: NM 299	Cytotoxicity against mock-infected african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay Cytotoxicity against mock-infected african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay	[PMID: 25082514]
Vero 76	CC₅₀	20 μM Compound: NM299	Cytotoxicity against african green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining method Cytotoxicity against african green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining method	[PMID: 26443549]

体外研究
(In Vitro)

6-Azuridine 在 ACE2 人细胞中表现出抗 COVID-19 的抗病毒活性，EC₅₀ 为 48 μM^[2]。
6-Azuridine (5 μM，最长 8 h) 可增加 L5178Y 小鼠淋巴瘤细胞中 5′-triphosphate 的水平，并降低尿嘧啶、胞嘧啶核苷酸^[3]。
6-Azuridine (5-20 μM，24 h) 通过 p53 和 AMPK 依赖性途径诱导各种人类癌细胞 (H460 和 H1299) 中自噬介导的细胞死亡^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

6-Azuridine (150 mg/kg，腹腔注射，每日，10-13 天) 对感染传染性胃肠炎病毒的猪表现出抗病毒活性^[5]。
6-Azuridine (30 mg/kg/天，口服，饮用水，39-41 天) 对小鼠的浆细胞肿瘤 (X-5563 和 X-5647) 表现出抗肿瘤作用^[6]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

245.19

Formula

C₈H₁₁N₃O₆

CAS 号

54-25-1

性状

固体

颜色

White to off-white

中文名称

氮杂尿苷

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

细胞实验：

DMSO 中的溶解度 : 25 mg/mL (101.96 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	4.0785 mL	20.3923 mL	40.7847 mL
5 mM	0.8157 mL	4.0785 mL	8.1569 mL
10 mM	0.4078 mL	2.0392 mL	4.0785 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (10.20 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (10.20 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案三

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (10.20 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.83%

选择批次：

Data Sheet (639 KB) SDS (644 KB)

COA (292 KB) HNMR (252 KB) RP-HPLC (262 KB) LCMS (103 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88. [Content Brief]

[2]. Yallappa G N, et al. Design and synthesis of pyrazole derivatives for in vitro screening to protect angiotensin-converting enzyme 2 human cells against COVID-19. Current Medicine Research and Practice, 2021, 11(5): 206-210.

[3]. Janeway CM, et al. Effects of 6-azauridine on nucleotides, orotic acid, and orotidine in L5178Y mouse lymphoma cells in vitro. Cancer Res. 1977 Dec;37(12):4382-8. [Content Brief]

[4]. Cha YE, et al. 6-Azauridine Induces Autophagy-Mediated Cell Death via a p53- and AMPK-Dependent Pathway. Int J Mol Sci. 2021 Mar 14;22(6):2947. [Content Brief]

[5]. Steffenhagen KA, et al. Evaluation of 6-azauridine and 5-iododeoxyuridine in the treatment of experimental viral infections. J Infect Dis. 1976 Jun;133(6):603-12. [Content Brief]

[6]. Conn HO, et al. Effect of 6-azauridine on plasma cell tumors of mice: correlation of antitumor effect with inhibition of orotic acid metabolism. Cancer Res. 1967 Apr;27(4):618-25. [Content Brief]

6-Azuridine 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	4.0785 mL	20.3923 mL	40.7847 mL	101.9617 mL
	5 mM	0.8157 mL	4.0785 mL	8.1569 mL	20.3923 mL
	10 mM	0.4078 mL	2.0392 mL	4.0785 mL	10.1962 mL
	15 mM	0.2719 mL	1.3595 mL	2.7190 mL	6.7974 mL
	20 mM	0.2039 mL	1.0196 mL	2.0392 mL	5.0981 mL
	25 mM	0.1631 mL	0.8157 mL	1.6314 mL	4.0785 mL
	30 mM	0.1359 mL	0.6797 mL	1.3595 mL	3.3987 mL
	40 mM	0.1020 mL	0.5098 mL	1.0196 mL	2.5490 mL
	50 mM	0.0816 mL	0.4078 mL	0.8157 mL	2.0392 mL
	60 mM	0.0680 mL	0.3399 mL	0.6797 mL	1.6994 mL
	80 mM	0.0510 mL	0.2549 mL	0.5098 mL	1.2745 mL
	100 mM	0.0408 mL	0.2039 mL	0.4078 mL	1.0196 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

6-Azuridine54-25-16-Azauridine氮杂尿苷Nucleoside Antimetabolite/AnalogAutophagyApoptosisAMPKMDM-2/p53SARS-CoVAMP-activated protein kinaseSARS coronavirusindolent lymphoid malignanciesantitumorantiviralInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

6-Azuridine (Synonyms: 6-Azauridine)

Customer Review

6-Azuridine 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 AMPK 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

6-Azuridine 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

6-Azuridine (Synonyms: 6-Azauridine)

Customer Review

6-Azuridine 相关抗体

6-Azuridine 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 AMPK 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

6-Azuridine 相关抗体:

摩尔计算器

稀释计算器

6-Azuridine 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z